Cutler Group’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

Cutler Group’s Portfolio CALT Stock Details CALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-100	Closed	-$2K	–	3884
2023 Q4	$2K	Buy	+100	New	+$1.87K	﹤0.01%	3233
2022 Q4	–	Sell	-220	Closed	-$3K	–	5428
2022 Q3	$3K	Sell	220 -340	-61%	-$5.92K	﹤0.01%	4088
2022 Q2	$10K	Sell	560 -1,440	-72%	-$25.1K	﹤0.01%	3234
2022 Q1	$37K	Buy	2,000 +1,630	+441%	+$32.7K	﹤0.01%	2520
2021 Q4	$9K	Buy	+370	New	+$7.43K	﹤0.01%	3822

Other funds holding CALT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

IIM

Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Cutler Group's CALT Position: Q1 2024 in Review

Cutler Group sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q1 2024, closing a stake of 100 shares — an estimated $2K sold.

Cutler Group first reported a position in CALT in Q4 2021 and held it in 5 quarters. The position peaked at $37K in Q1 2022. 19 funds tracked by Wall St. Rank hold CALT as of Q1 2024.

Cutler Group reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q1 2024 after selling out during the quarter.
Cutler Group sold 100 Calliditas Therapeutics AB American Depositary Shares shares in Q1 2024, an estimated $2K.
Cutler Group first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q4 2021 and held it in 5 quarters.
Cutler Group's Calliditas Therapeutics AB American Depositary Shares position peaked at $37K in Q1 2022.
19 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.